- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01166425
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania. (Lithium2)
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The following are the objectives of this study:
- To determine if lithium is more efficacious in reducing symptoms of mania than placebo.
- To describe the short-term safety of lithium in the pediatric population relative to placebo treatment.
- To examine the effectiveness and efficacy of lithium as a maintenance treatment for children and adolescents with bipolar I disorder.
- To examine the long-term and short-term safety and tolerability of lithium in pediatric bipolar I disorder.
- To examine the effects of lithium treatment over time on specific aspects of cognitive functioning that have been reported to be adversely affected by lithium in the adult population.
- More specifically, to determine the integrity of fine-motor, attention, verbal memory, and selected executive function domains prior to treatment at baseline, at the end of week 8/early termination of the Efficacy Phase, and at the end of week 24/early termination from the Long- Term Effectiveness Phase (after 24/32 weeks of lithium treatment).
- To examine the relationship between systemic exposure to lithium and effectiveness and toxicity.
- To examine the long-term safety and tolerability of combination therapy, lithium plus other psychotropic agents, in pediatric bipolar I disorder.
- To critically assess the efficacy of lithium for prophylaxis against recurrence of mood symptoms in children and adolescents.
- In those participants who discontinue treatment with lithium and experience a mood relapse, to determine the duration of lithium treatment necessary before re-stabilization is achieved.
- To evaluate the influence of intrinsic factors [e.g. age, gender, race, renal function, height, (measured by stadiometer) and weight] on lithium exposure.
The Study population for this study: Children and adolescents 7- 17 years of age who meet DSM-IV diagnostic criteria for Bipolar I (mania, mixed mania) without psychotic symptoms as determined by a child and adolescent psychiatrist will be eligible for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Childrens National Medical Center
-
-
Illinois
-
South Chicago Heights, Illinois, United States, 60612
- University of Illinois at Chicago
-
-
Kansas
-
Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, Kansas, United States, 67214
- University of Kansas School of Medicine
-
-
Massachusetts
-
Biotech One Suite 100, 365 Plantation, Worcester, Massachusetts, United States, 01605
- University of Massachusetts Medical School
-
-
New York
-
Glen Oaks, New York, United States, 11004
- The Zucker Hillside Hospital
-
New York, New York, United States, 10032
- Columbia University
-
-
North Carolina
-
Department of Psychiatry, CB 7160, Chapel Hill, North Carolina, United States, 27599
- University of North Carolina - Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati
-
Cincinnati, Ohio, United States, 10032
- Cincinnati Childrens Hospital Medical Center
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98101
- Seattle Childrens Hospital Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants aged 7 years to 17 years, 11 months old at time of first dose
- Participants must meet DSM-IV diagnostic criteria, as assessed by a semi-structured assessment (KSADS-PL) and a separate clinical interview with a child/adolescent psychiatrist for manic or mixed episodes in bipolar I disorder
- Score of > 20 on the YMRS at screening and baseline
- The participant and legal guardian must understand the nature of the study and be able to comply with protocol requirements. The legal guardian must give written informed consent and the youth, written assent
- Participants with comorbid conditions [attention deficit hyperactivity disorder (ADHD), conduct disorder], except those listed in Exclusion Criterion 2, may participate
- If female: is premenarchal, or is incapable of pregnancy because of a hysterectomy, tubal ligation, or spousal/partner sterility. If sexually active and capable of pregnancy, has been using an acceptable method of contraception (hormonal contraceptives, intrauterine device, spermicide and barrier) for at least one month prior to study entry and agrees to continue to use one of these for the duration of the study. If sexually abstinent and capable of pregnancy, agrees to continued abstinence or to use of an acceptable method of birth control should sexual activity commence
- Has a negative quantitative serum ß-human chorionic gonadotrophin hormone pregnancy test at screening and a negative qualitative urine pregnancy test at baseline, if female
- Participants with a history of substance abuse may participate if they agree to continue to abstain from drugs during the trial and have a negative drug screen at screening or prior to baseline. Those with an initial positive drug screen during screening may have another screen done 1-3 weeks later while in screening, and a negative result will allow the participant to participate
- The participant is willing and clinically able to wash out of exclusion medications during the screening period. Prior to the administration of lithium, participants will have not used any of the following medications: antipsychotics, monoamine oxidase inhibitors, antidepressants within the preceding 2 weeks; stimulants within the preceding week; or fluoxetine or depot antipsychotics in the past month (no stable participants will be asked to discontinue medications)
- ECG and bloodwork including CBC, electrolytes, etc. (as per Safety assessment procedures listed in Table 6) showing no clinically significant abnormalities
Exclusion Criteria:
- Participant who is clinically stable on current medication regimen for bipolar disorder
- A current or lifetime diagnosis of Schizophrenia or Schizoaffective Disorder, a Pervasive Developmental Disorder (ASQ score > 15), Anorexia Nervosa, Bulimia Nervosa, or Obsessive-Compulsive Disorder
- Current DSM-IV diagnosis of Substance Dependence
- Positive drug screen at screening and on retest 1-3 weeks later
- Participants with symptoms of mania that may be attributable to a general medical condition, or secondary to use of medications (e.g., corticosteroids)
- Evidence of any serious, unstable neurological illness for which treatment under the auspices of this study would be contraindicated
- Any serious, unstable medical illness or clinically significant abnormal laboratory assessments that would adversely impact the scientific interpretability or unduly increase the risks of the protocol
- Current general medical condition including neurological disease, diabetes mellitus, thyroid dysfunction, or renal dysfunction that might be affected adversely by lithium, could influence the efficacy or safety of lithium, or would complicate interpretation of study results
- Evidence of current serious homicidal/suicidal ideation such that in the treating physician's opinion it would not be appropriately safe for the participant to participate in this study
- Evidence of current active hallucinations and delusions such that in the treating physician's opinion it would not be appropriately safe for the participant to participate in this study
- Concomitant prescription of over-the-counter medication or nutritional supplements (e.g., ibuprofen, naproxen, St John's wort) that would interact with lithium or affect the participant's physical or mental status
- Concomitant psychotherapy treatments provided outside the study initiated within 4 weeks prior to screening
- Previous adequate trial with Li+ (at least 4 weeks with Li+ serum levels between 0.8-1.2 mEq/L)
- History of allergy to lithium or lithium intolerance
- Psychiatric hospitalization within 1 month of screening for psychosis or serious homicidal/serious suicidal ideation
- Clinician's judgment that participant is not likely to be able to complete the study as an outpatient due to psychiatric reasons
- Females who are currently pregnant or lactating
- Sexually active females who, in the investigators' opinion, are not using an adequate form of birth control.
- Participants who are unable to swallow the study medication
- Participants for whom a baseline YMRS score of < 20 is anticipated
- Participants with an IQ less than 70 (determined using the Wechsler Abbreviated Scales of Intelligence {WASI} Vocabulary and Matrix Reasoning Subscales)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Lithium Carbonate
Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID (three times a day) at visit 1 (total dose 900 mg).
Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID (two times a day) the day after visit 1 (total dose 600 mg).
Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
|
Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg).
Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg).
Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits.
On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian.
During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
Other Names:
|
PLACEBO_COMPARATOR: placebo
Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules.
Dosing will be titrated as described for active lithium.
|
Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules.
Dosing will be titrated as described for active lithium.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
YMRS score
Time Frame: >17 months
|
Significant changes in YMRS scores from baseline to the end of each study phase. YMRS scores are questionnaires to assess pediatric mania. |
>17 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Global Impressions Scale- Severity and Improvement
Time Frame: >17 months
|
>17 months
|
Children Depression Rating Scale-Revised
Time Frame: >17 months
|
>17 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Robert Findling, MD, University Hospitals Cleveland Medical Center
Publications and helpful links
General Publications
- Findling RL, McNamara NK, Pavuluri M, Frazier JA, Rynn M, Scheffer R, Kafantaris V, Robb A, DelBello M, Kowatch RA, Rowles BM, Lingler J, Zhao J, Clemons T, Martz K, Anand R, Taylor-Zapata P. Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. J Am Acad Child Adolesc Psychiatry. 2019 Feb;58(2):287-296.e4. doi: 10.1016/j.jaac.2018.07.901. Epub 2018 Nov 26.
- Findling RL, Robb A, McNamara NK, Pavuluri MN, Kafantaris V, Scheffer R, Frazier JA, Rynn M, DelBello M, Kowatch RA, Rowles BM, Lingler J, Martz K, Anand R, Clemons TE, Taylor-Zapata P. Lithium in the Acute Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study. Pediatrics. 2015 Nov;136(5):885-94. doi: 10.1542/peds.2015-0743. Epub 2015 Oct 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NICHD-2005-07-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on Lithium Carbonate
-
Northwestern UniversityCompletedBipolar DisorderUnited States
-
New York State Psychiatric InstituteNational Institute on Aging (NIA)CompletedPsychosis | Alzheimer's Disease | AgitationUnited States
-
Shanghai Mental Health CenterUnknown
-
The University of Hong KongChina Spinal Cord Injury NetworkCompletedSpinal Cord InjuriesChina
-
University of Wisconsin, MadisonTerminatedMedullary Thyroid CancerUnited States
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
University of Maryland, BaltimoreCompletedOsteoporosis PseudogliomaUnited States
-
University of OxfordCompleted
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPrimary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedSolid Tumor | Brain and Central Nervous System Tumors | Neurotoxicity | Cognitive/Functional EffectsUnited States